Evotec SE Cash Flow Conversion Efficiency
Evotec SE cash flow conversion efficiency. Based on the latest financial reports, Evotec SE (EVT) has a cash flow conversion efficiency ratio of -0.162x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-107.83 Million ≈ $-126.06 Million USD) by net assets (€665.58 Million ≈ $778.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Evotec SE (2003–2025)
Cash flow conversion efficiency of Evotec SE from 2003 to 2025. This chart illustrates how Evotec SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Evotec SE for real-time trading data and today's change.
Evotec SE Cash Flow Conversion Ratio Explained
Evotec SE cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Evotec SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ranked by their cash flow conversion efficiency. Also see market value of Evotec SE for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marssenger Kitchenware Co. Ltd.
SHE:300894
|
-0.054x |
|
Pum-Tech Korea Co. Ltd
KQ:251970
|
0.049x |
|
MTY Food Group Inc
TO:MTY
|
0.048x |
|
Sinon Corp
TW:1712
|
0.058x |
|
PIERER Mobility AG
VI:PKTM
|
0.049x |
|
Asia Aviation Public Company Limited
BK:AAV-R
|
0.164x |
|
Hubei Kailong Chemical Group Co Ltd
SHE:002783
|
0.000x |
|
First Sensor AG
F:SIS
|
0.034x |
Annual Cash Flow Conversion Efficiency for Evotec SE (2003–2025)
The table below shows the annual cash flow conversion efficiency of Evotec SE from 2003 to 2025. Review Evotec SE free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €813.70 Million ≈ $951.31 Million |
€-9.44 Million ≈ $-11.03 Million |
-0.012x | -160.63% |
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
€18.22 Million ≈ $21.30 Million |
0.019x | -41.21% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
€36.44 Million ≈ $42.60 Million |
0.033x | -80.98% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
€203.11 Million ≈ $237.45 Million |
0.171x | +92.82% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€122.24 Million ≈ $142.91 Million |
0.089x | +43.84% |
| 2020-12-31 | €725.01 Million ≈ $847.62 Million |
€44.72 Million ≈ $52.28 Million |
0.062x | -30.30% |
| 2019-12-31 | €477.03 Million ≈ $557.70 Million |
€42.22 Million ≈ $49.35 Million |
0.088x | -75.93% |
| 2018-12-31 | €424.88 Million ≈ $496.73 Million |
€156.24 Million ≈ $182.66 Million |
0.368x | +1026.64% |
| 2017-12-31 | €331.75 Million ≈ $387.85 Million |
€10.83 Million ≈ $12.66 Million |
0.033x | -89.63% |
| 2016-12-31 | €213.94 Million ≈ $250.11 Million |
€67.36 Million ≈ $78.75 Million |
0.315x | +276.39% |
| 2015-12-31 | €187.09 Million ≈ $218.73 Million |
€15.65 Million ≈ $18.30 Million |
0.084x | +448.94% |
| 2014-12-31 | €158.38 Million ≈ $185.17 Million |
€-3.80 Million ≈ $-4.44 Million |
-0.024x | -157.25% |
| 2013-12-31 | €158.97 Million ≈ $185.85 Million |
€6.66 Million ≈ $7.78 Million |
0.042x | -46.57% |
| 2012-12-31 | €152.55 Million ≈ $178.34 Million |
€11.96 Million ≈ $13.98 Million |
0.078x | +13.75% |
| 2011-12-31 | €147.25 Million ≈ $172.14 Million |
€10.15 Million ≈ $11.86 Million |
0.069x | +916.62% |
| 2010-12-31 | €132.64 Million ≈ $155.07 Million |
€899.00K ≈ $1.05 Million |
0.007x | +103.46% |
| 2009-12-31 | €111.49 Million ≈ $130.34 Million |
€-21.85 Million ≈ $-25.55 Million |
-0.196x | +28.84% |
| 2008-12-31 | €149.86 Million ≈ $175.20 Million |
€-41.28 Million ≈ $-48.26 Million |
-0.275x | -48.33% |
| 2007-12-31 | €170.55 Million ≈ $199.39 Million |
€-31.67 Million ≈ $-37.03 Million |
-0.186x | -176.14% |
| 2006-12-31 | €137.18 Million ≈ $160.37 Million |
€-9.22 Million ≈ $-10.78 Million |
-0.067x | -367.85% |
| 2005-12-31 | €148.67 Million ≈ $173.81 Million |
€-2.14 Million ≈ $-2.50 Million |
-0.014x | +95.23% |
| 2004-12-31 | €61.73 Million ≈ $72.17 Million |
€-18.60 Million ≈ $-21.74 Million |
-0.301x | +22.58% |
| 2003-12-31 | €36.03 Million ≈ $42.12 Million |
€-14.02 Million ≈ $-16.39 Million |
-0.389x | -- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more